Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00519233
Status:
COMPLETED
Last Update Posted:
2014-05-02
First Post:
2007-08-20
Brief Title:
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study will investigate the safety tolerability and spectrum of side effects of AGS-1C4D4 As such this study will characterize the dose limiting toxicities DLT and potentially the maximum tolerated dose MTD of AGS-1C4D4 in patients with advanced HRPC
Detailed Description:
Cohorts of 1-6 patients will be administered AGS-1C404 in sequentially rising dose levels Dose escalation will continue until the MTD of AGS-1C4D4 is established or the maximum planned dose is reached
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_535 | None | None | None |
| MK4721-003 | None | None | None |